Skip to content

Study · Observational study · n = 50 · 2024

4 results

[Results of a pilot study of the structure and evaluation of the therapy for chronic sleep disorders in comorbid patients with chronic cerebral ischemia].

Putilina MV, Shabalina NI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2024Cited by 1 (Europe PMC)

PMID38676686 (opens in a new tab)DOI10.17116/jnevro2024124041118 (opens in a new tab)PepBankPUB-38676686
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with cerebral ischemia and insomnia, main complaints regressed after Cortexin, with clinical changes evident by days 11-15 and persisting for one month.

    In plain wordsPatients with cerebral ischemia and insomnia had fewer complaints after Cortexin, with clinical changes evident by days 11-15 and persisting for one month.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseMain complaints
    Study

    n = 50

    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    After treatment, there was a regression of the main complaints, the severity of symptoms, including anxiety and depression, decreased, and a significant stabilization of cognitive status was observed.
    4 context sentences
    Summary · context
    The study included 50 patients, average age 50.4±2.26 years, with CHI stage 1-2. with concomitant diseases arterial hypertension, atherosclerosis, diabetes mellitus (study CHRONAS).
    Summary · context
    The positive dynamics persisted 1 month after the end of therapy.
    Summary · context
    Clinical dynamics were recorded already by the 11-15th day of treatment and persisted for up to 1 month.
    Summary · context
    The clinical effectiveness of the drug Cortexin at a dose of 10 mg IM for 10 days has been proven in patients with chronic sleep disorders due to CHI.
  2. 02HumanObservational studyEfficacy outcome

    In patients with cerebral ischemia and insomnia, the severity of symptoms, including anxiety and depression, decreased after Cortexin treatment.

    In plain wordsIn patients with chronic brain ischemia and insomnia, symptoms including anxiety and depression decreased after Cortexin treatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    DecreaseAnxiety and depression symptoms
    Study

    n = 50

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    10 mg · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    After treatment, there was a regression of the main complaints, the severity of symptoms, including anxiety and depression, decreased, and a significant stabilization of cognitive status was observed.
    1 context sentence
    Summary · context
    The study included 50 patients, average age 50.4±2.26 years, with CHI stage 1-2. with concomitant diseases arterial hypertension, atherosclerosis, diabetes mellitus (study CHRONAS).
  3. 03HumanObservational studyEfficacy outcome

    In patients with cerebral ischemia and insomnia, cognitive status stabilized significantly after Cortexin treatment.

    In plain wordsPatients with cerebral ischemia and insomnia showed significant cognitive stabilization after Cortexin treatment.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Direction not reportedCognitive status stabilization
    Study

    n = 50

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 mg · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    After treatment, there was a regression of the main complaints, the severity of symptoms, including anxiety and depression, decreased, and a significant stabilization of cognitive status was observed.
    1 context sentence
    Summary · context
    The study included 50 patients, average age 50.4±2.26 years, with CHI stage 1-2. with concomitant diseases arterial hypertension, atherosclerosis, diabetes mellitus (study CHRONAS).
  4. 04HumanObservational studySafety outcome

    No patient with cerebral ischemia had adverse interactions between Cortexin and concomitant drugs during observation.

    In plain wordsNo patient had adverse interactions between Cortexin and their other drugs during observation.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableAdverse drug interactions
    Study

    n = 50

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 mg · intramuscular · 10 daysAs given in this study (human).

    Source sentences

    Summary
    During observation, no patient had adverse drug interactions with other drugs (hypotensives, antiplatelet agents, statins).
    1 context sentence
    Summary · context
    The study included 50 patients, average age 50.4±2.26 years, with CHI stage 1-2. with concomitant diseases arterial hypertension, atherosclerosis, diabetes mellitus (study CHRONAS).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.